AccuraGen Passed CAP NGSST-PT with Full Marks Again

Recently, The next generation sequencing (NGS) laboratory under AccuraGen Holdings passed the Next Generation Sequence Solid Tumor (NGSST) Proficiency Testing (PT) assessment launched by College of American Pathologists (CAP) with full marks again.

The testing conducted by AccuraGen this time is targeted at the next generation sequencing of 61 tumor target-related hotspot genes, covering thewhole process of sequencing experiments, data analysis and clinical annotation.The results generated from AccuraGen Clinical Laboratory and standard resultspublished by CAP are completely consistent.

Since the year of 2017, AccuraGen has passed the NGSST proficiency test for several times. Earlier this year, it passed the CAP accreditation andobtained the laboratory competence certificate for both liquid biopsy ctDNA-NGSand tissue gDNA-NGS projects. Passing PT with full marks this time fully showsthat AccuraGen has strong scientific research strength, advanced analysis platform and strict standards and regulations in the fields of liquid biopsyand tissue sequencing.

AccuraGen has always adhered to the core values ​​of “Inventing the future of cancer diagnostics”, is committed to and specializes in next generation sequencing of genes and its application in precision cancer treatment, and has always optimized NGS laboratory.